Abstract
To meet challenges in terms of throughput and turnaround time, many diagnostic laboratories are shifting from Sanger sequencing to higher throughput next-generation sequencing (NGS) platforms. Bearing in mind that the performance and quality criteria expected from NGS in diagnostic or research settings are strikingly different, we have developed an Ion Torrent’s PGM-based routine diagnostic procedure for BRCA1/2 sequencing. The procedure was first tested on a training set of 62 control samples, and then blindly validated on 77 samples in parallel with our routine technique. The training set was composed of difficult cases, for example, insertions and/or deletions of various sizes, large-scale rearrangements and, obviously, mutations occurring in homopolymer regions. We also compared two bioinformatic solutions in this diagnostic context, an in-house academic pipeline and the commercially available NextGene software (Softgenetics). NextGene analysis provided higher sensitivity, as four previously undetected single-nucleotide variations were found. Regarding specificity, an average of 1.5 confirmatory Sanger sequencings per patient was needed for complete BRCA1/2 screening. Large-scale rearrangements were identified by two distinct analyses, that is, bioinformatics and fragment analysis with electrophoresis profile comparison. Turnaround time was enhanced, as a series of 30 patients were sequenced by one technician, making the results available for the clinician in 10 working days following blood sampling. BRCA1/2 genes are a good model, representative of the difficulties commonly encountered in diagnostic settings, which is why we believe our findings are of interest for the whole community, and the pipeline described can be adapted by any user of PGM for diagnostic purposes.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Shanks ME, Downes SM, Copley RR et al: Next-generation sequencing (NGS) as a diagnostic tool for retinal degeneration reveals a much higher detection rate in early-onset disease. Eur J Hum Genet 2013; 21: 274–280.
Artuso R, Fallerini C, Dosa L et al: Advances in Alport syndrome diagnosis using next-generation sequencing. Eur J Hum Genet 2012; 20: 50–57.
Ozcelik H, Shi X, Chang MC et al: Long-range PCR and next-generation sequencing of BRCA1 and BRCA2 in breast cancer. J Mol Diagn 2012; 14: 467–475.
Pern F, Bogdanova N, Schurmann P et al: Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. PLoS One 2012; 7: e47993.
Feliubadalo L, Lopez-Doriga A, Castellsague E et al: Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. Eur J Hum Genet 2013; 864–870.
Stoppa-Lyonnet D, Laurent-Puig P, Essioux L et al: BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet 1997; 60: 1021–1030.
Caux-Moncoutier V, Castera L, Tirapo C et al: EMMA, a cost- and time-effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: application to BRCA1 and BRCA2 in 1,525 patients. Hum Mutat 2011; 32: 325–334.
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G : Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30: e57.
Rothberg JM, Hinz W, Rearick TM et al: An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011; 475: 348–352.
Houdayer C, Caux-Moncoutier V, Krieger S et al: Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat 2012; 33: 1228–1238.
San Lucas FA, Wang G, Scheet P, Peng B : Integrated annotation and analysis of genetic variants from next-generation sequencing studies with variant tools. Bioinformatics 2011; 28: 421–422.
McKenna A, Hanna M, Banks E et al: The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297–1303.
Anders S, Huber W : Differential expression analysis for sequence count data. Genome Biol 2010; 11: R106.
Wang K, Li M, Hakonarson H : ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38: e164.
Hochberg Y, Benjamini Y : More powerful procedures for multiple significance testing. Stat Med 1990; 9: 811–818.
Goecks J, Nekrutenko A, Taylor J : Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol 2010; 11: R86.
Michils G, Hollants S, Dehaspe L et al: Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing. J Mol Diagn 2012; 14: 623–630.
Machado PM, Brandao RD, Cavaco BM et al: Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 2007; 25: 2027–2034.
Bell CJ, Dinwiddie DL, Miller NA et al: Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 2011; 3: 65ra64.
De Leeneer K, De Schrijver J, Clement L et al: Practical tools to implement massive parallel pyrosequencing of PCR products in next generation molecular diagnostics. PLoS One 2011; 6: e25531.
Acknowledgements
We thank Dr Laurent Castéra for helpful support during the ‘technology selection’ phase, Anthony Laugé for LIMS optimization, Alain Nicolas for fruitful discussions and the referring clinicians. This work was supported by funding from ICGex, CEST Institut Curie and INCa/DGOS ‘Recherche translationnelle sur le cancer, and Séquençage haut debit et predisposition aux cancers du sein’. NGS projects were also supported by grants from Canceropôle Ile de France and the Region Ile de France (Seq-Start).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on European Journal of Human Genetics website
Supplementary information
Rights and permissions
About this article
Cite this article
Tarabeux, J., Zeitouni, B., Moncoutier, V. et al. Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model. Eur J Hum Genet 22, 535–541 (2014). https://doi.org/10.1038/ejhg.2013.181
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2013.181
Keywords
This article is cited by
-
Prevalence of BRCA homopolymeric indels in an ION Torrent-based tumour-to-germline testing workflow in high-grade ovarian carcinoma
Scientific Reports (2023)
-
Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer
Scientific Reports (2019)
-
Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition
Breast Cancer Research and Treatment (2018)
-
Statistical method to compare massive parallel sequencing pipelines
BMC Bioinformatics (2017)
-
Mosaicism and prenatal diagnosis options: insights from retinoblastoma
European Journal of Human Genetics (2017)
